Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity

Doxorubicin (Dox) is a potent anticancer agent; its clinical use is limited for its marked cardiotoxicity and nephrotoxicity. The present study investigated the possible protective effect of telmisartan, an angiotensin AT(1)-receptor blocker versus captopril, an angiotensin-converting enzyme inhibit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacological research 2009-11, Vol.60 (5), p.373
Hauptverfasser:	Ibrahim, Mohamed A, Ashour, Osama M, Ibrahim, Yasmin F, El-Bitar, Hussian I, Gomaa, Wafaey, Abdel-Rahim, Salama R
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin II Type 1 Receptor Blockers - pharmacology Angiotensin-Converting Enzyme Inhibitors - pharmacology Animals Antibiotics, Antineoplastic - adverse effects Benzimidazoles - pharmacology Benzoates - pharmacology Captopril - pharmacology Doxorubicin - adverse effects Glutathione - metabolism Glutathione Peroxidase - metabolism Heart - drug effects Kidney - drug effects Kidney - metabolism Kidney - pathology Lipid Peroxidation - drug effects Male Myocardium - metabolism Myocardium - pathology Nitric Oxide - metabolism Nitric Oxide Synthase Type II - metabolism Rats Superoxide Dismutase - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!